Effects of SGLT2 inhibitors on cardiac function and health status in chronic heart failure: a systematic review and meta-analysis
Abstract Purpose Numerous clinical studies have explored sodium–glucose cotransporter 2 inhibitor (SGLT2i) in patients with chronic heart failure (CHF), with or without type 2 diabetes mellitus (T2DM), and SGLT2i were proved to significantly reduce CHF hospitalization, cardiovascular death, cardiova...
Main Authors: | Jiao Chen, Chunxia Jiang, Man Guo, Yan Zeng, Zongzhe Jiang, Dongmin Zhang, Mengqin Tu, Xiaozhen Tan, Pijun Yan, XunMei Xu, Yang Long, Yong Xu |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2024-01-01
|
Series: | Cardiovascular Diabetology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12933-023-02042-9 |
Similar Items
-
Impact of SGLT2 inhibition on markers of reverse cardiac remodelling in heart failure: Systematic review and meta‐analysis
by: Patrick Savage, et al.
Published: (2024-12-01) -
Redefining outcomes of ventricular arrhythmia for SGLT2 inhibitor medication in heart failure patients: a meta-analysis of randomized controlled trials
by: Miao Lin, et al.
Published: (2025-02-01) -
Targeting high glucose-induced epigenetic modifications at cardiac level: the role of SGLT2 and SGLT2 inhibitors
by: Lucia Scisciola, et al.
Published: (2023-02-01) -
Dapagliflozin prevents ERK activation and SGLT2‐dependent endoglin upregulation in a mechanically provoked cardiac injury model
by: Tung‐Chen Yeh, et al.
Published: (2024-04-01) -
SGLT2 inhibition, venous thrombolism, and death due to cardiac causes: a mediation Mendelian randomization study
by: Lili Shi, et al.
Published: (2024-05-01)